Anti-Anginal Drugs Calcium Antagonists Cardiac Drugs: MIMS Class
Anti-Anginal Drugs Calcium Antagonists Cardiac Drugs: MIMS Class
Anti-Anginal Drugs Calcium Antagonists Cardiac Drugs: MIMS Class
Bayer [ Zuellig ]
MIMS Class : Anti-Anginal Drugs, Calcium Antagonists, Cardiac Drugs
Treatment of hypertension.
Dosage As much as possible, the treatment must be tailored to the
needs of the individual.
Incompatibilities: None.
View more drug interactions for Adalat
Pregnancy Category
(US FDA)
Category C: Either studies in animals have revealed adverse
effects on the foetus (teratogenic or embryocidal or other) and
there are no controlled studies in women or studies in women
and animals are not available. Drugs should be given only if
the potential benefit justifies the potential risk to the foetus.
Cautions For Usage In Adalat GITS 20/30/60, nifedipine is contained within a
nonabsorbable shell that slowly releases the drug for the body
to absorb. When this process is completed, the empty tablet is
eliminated from the body and may be noticed in the stool.
Pfizer [ Zuellig ]
MIMS Class : ACE Inhibitors
When ACE inhibitors have been used during the 2nd and 3rd
trimesters of pregnancy, there have been reports of
hypotension, renal failure, skull hypoplasia, and/or death in the
newborn. Oligohydramnios has also been reported,
presumably representing decreased renal function in the fetus;
limb contractures, craniofacial deformities, hypoplastic lung
development and intrauterine growth retardation have been
reported in association with oligohydramnios. While these
adverse effects do not appear to have been the result of
exposure limited to the 1st trimester, mothers whose embryos
and fetuses have been exposed only during the 1st trimester,
must be so informed. Nonetheless, should a woman become
pregnant while receiving ACE inhibitors, the drug should be
discontinued as soon as possible.
Patients who do require ACE inhibitors during the 2nd and 3rd
trimesters of pregnancy should be apprised of the potential
hazards to the fetus; frequent ultrasound examinations should
be performed to detect oligohydramnios. Patients and
physicians should be aware, however that oligohydramnios
may not appear until after the fetus has sustained irreversible
injury. If oligohydramnios is observed, quinapril should be
discontinued unless it is considered life-saving for the mother.